Loading...
Market
Ionis presents additional positive data at a major medical conference by Nov 30?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Conference presentations and press releases
Story
Ionis Reports Positive Results for Donidalorsen in OASIS-HAE and OASISplus Trials
May 31, 2024, 03:02 PM
Ionis Pharmaceuticals has announced positive results from two late-stage trials, OASIS-HAE and OASISplus, for its investigational therapy donidalorsen in treating hereditary angioedema (HAE). The trials demonstrated that donidalorsen, which targets prekallikrein mRNA, significantly reduced the attack rate in patients compared to a placebo. These benefits were observed even in patients currently on other HAE medications. $IONS (-1.0% pre).
View original story
Similar markets
EAACI 2024 Congress • 25%
American Society of Hematology (ASH) Annual Meeting • 25%
European Society of Cardiology (ESC) Congress • 25%
American Association for the Study of Liver Diseases (AASLD) Liver Meeting • 25%
Phase III trial in the US • 25%
Approval in China • 25%
Approval in the EU • 25%
Partnership with another pharmaceutical company • 25%